- Home
- OBX vs RERE Comparison
OBX vs RERE Comparison
Compare OBX & RERE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OBX | RERE |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 861.1M | 832.8M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OBX | RERE |
|---|---|---|
| Price | $14.58 | $4.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $39.00 | $6.64 |
| AVG Volume (30 Days) | 364.3K | ★ 477.3K |
| Earning Date | 11-13-2026 | 11-19-2026 |
| Dividend Yield | N/A | ★ 2.33% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $27.40 |
| Revenue Next Year | N/A | $21.96 |
| P/E Ratio | ★ N/A | $34.57 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.60 | $3.50 |
| 52 Week High | $39.00 | $6.47 |
Technical Indicators
Market Signals| Indicator | OBX | RERE |
|---|---|---|
| Relative Strength Index (RSI) | 49.72 | 69.52 |
| Support Level | $11.84 | $4.31 |
| Resistance Level | $15.87 | $4.77 |
| Average True Range (ATR) | 1.73 | 0.17 |
| MACD | -0.04 | 0.06 |
| Stochastic Oscillator | 64.91 | 97.42 |
Price Performance
Historical ComparisonAbout OBX Obsidian Therapeutics Inc. Common Stock
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platforms PJT Marketplace and Paipai Marketplace. The Company's principal operations and geographic markets are in the People's Republic of China.